- Home
- BXSL vs HALO Comparison
BXSL vs HALO Comparison
Compare BXSL & HALO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BXSL
- HALO
- Stock Information
- Founded
- BXSL 2018
- HALO 1998
- Country
- BXSL United States
- HALO United States
- Employees
- BXSL N/A
- HALO N/A
- Industry
- BXSL Trusts Except Educational Religious and Charitable
- HALO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BXSL Finance
- HALO Health Care
- Exchange
- BXSL Nasdaq
- HALO Nasdaq
- Market Cap
- BXSL 7.5B
- HALO 7.4B
- IPO Year
- BXSL N/A
- HALO N/A
- Fundamental
- Price
- BXSL $31.16
- HALO $53.93
- Analyst Decision
- BXSL Buy
- HALO Buy
- Analyst Count
- BXSL 6
- HALO 9
- Target Price
- BXSL $31.38
- HALO $63.56
- AVG Volume (30 Days)
- BXSL 897.7K
- HALO 3.3M
- Earning Date
- BXSL 05-07-2025
- HALO 05-06-2025
- Dividend Yield
- BXSL 9.88%
- HALO N/A
- EPS Growth
- BXSL N/A
- HALO 55.40
- EPS
- BXSL 3.14
- HALO 3.76
- Revenue
- BXSL $1,380,706,000.00
- HALO $1,084,306,000.00
- Revenue This Year
- BXSL $12.37
- HALO $25.77
- Revenue Next Year
- BXSL $8.12
- HALO $18.01
- P/E Ratio
- BXSL $9.93
- HALO $14.34
- Revenue Growth
- BXSL 16.76
- HALO 25.64
- 52 Week Low
- BXSL $25.89
- HALO $42.01
- 52 Week High
- BXSL $34.64
- HALO $70.51
- Technical
- Relative Strength Index (RSI)
- BXSL 56.69
- HALO 43.12
- Support Level
- BXSL $29.07
- HALO $47.50
- Resistance Level
- BXSL $32.05
- HALO $69.94
- Average True Range (ATR)
- BXSL 0.52
- HALO 3.40
- MACD
- BXSL 0.26
- HALO -0.89
- Stochastic Oscillator
- BXSL 70.13
- HALO 27.94
About BXSL Blackstone Secured Lending Fund of Beneficial Interest
Blackstone Secured Lending Fund is a non-diversified, closed-end management investment company. The investment objectives of the company are to generate current income and, to a lesser extent, long-term capital appreciation. The company seeks to achieve its investment objectives by investing in originated loans and other securities, including syndicated loans of private U.S. companies, typically in the form of first lien senior secured and unitranche loans, unsecured and subordinated loans, and other securities.
About HALO Halozyme Therapeutics Inc.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.